ConjuChem

ConjuChem Biotechnologies Inc. is a medical biotechnology company located in Montreal, Quebec, Canada[1] which is credited with inventing the experimental peptide hormone CJC-1295.[2][3]

ConjuChem Biotechnologies Inc.
TypePublic (TSX has Delisted this Stock)
IndustryBiotechnology
Headquarters,
Key people
Mark Perrin
ProductsDrug Affinity Construct (DAC) and Preformed Conjugate-Drug Affinity Construct (PC-DAC)
Number of employees
44
Websitewww.conjuchem.com

It employs 45 people, 90% of whom are in research and development.

References

  1. "Conjuchem Biotechnologies Inc". Bloomberg Business. Retrieved 18 June 2015.
  2. Teichman, Sam L.; Neale, Ann; Lawrence, Betty; Gagnon, Catherine; Castaigne, Jean-Paul; Frohman, Lawrence A. (2006). "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults". The Journal of Clinical Endocrinology & Metabolism. 91 (3): 799–805. doi:10.1210/jc.2005-1536. ISSN 0021-972X. PMID 16352683.
  3. "CJC-1295 or Modified GRF (1-29)". American Science Labs. 9 February 2015. Archived from the original on 18 June 2015. Retrieved 18 June 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.